SCHEMBL21577992

SCHEMBL21577992

CCOC(=O)c1ccc(CC(C)CCC(=O)NOCc2oc(=O)oc2C)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.65
HTT P42858 3/20 0.38
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA12 O43570 1/20 0.36
ESR1 P03372 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
ESR2 Q92731 1/20 0.36
CA14 Q9ULX7 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 5/20 0.36
PRSS1 P07477 2/20 0.36
TMPRSS15 P98073 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAOA P21397 1/20 0.36
ALDH1A1 P00352 5/20 0.35
MEN1 O00255 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20179142 0.90 FOLH1 (0.72) FOLH1HTTCA1CA2CA12
SCHEMBL21577914 0.89 FOLH1 (0.80) FOLH1PRSS1TMPRSS15NPC1RAB9A
SCHEMBL20179133 0.89 FOLH1 (0.82) FOLH1HTTCA1CA2CA12
SCHEMBL21578141 0.89 FOLH1 (0.62) FOLH1CA1CA2CA12CA9
SCHEMBL20179247 0.88 FOLH1 (0.61) FOLH1HTTCA1CA2CA12
SCHEMBL21577995 0.78 HTT (0.39) FOLH1HTTCA1CA2CA12
SCHEMBL21577934 0.77 HTT (0.45) HTTCA1CA2CA12ESR1
SCHEMBL26038808 0.77 FOLH1 (0.76) FOLH1NPC1RAB9A
SCHEMBL21578072 0.77 HDAC3 (0.49) FOLH1HTTCA1CA2CA12
SCHEMBL21570573 0.76 FOLH1 (0.80) FOLH1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2021-11-18 US disclosed
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-13 US disclosed
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2019-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS GPI, TPI1, HPGDS FOLH1 10/4885HTT 2038/4885CA1 445/4885
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS TPI1, HPGDS, GPI FOLH1 39/4885HTT 1518/4885CA1 727/4885
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors GLS, HPGDS, GPI FOLH1 15/4885HTT 2017/4885CA1 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.